Clinical-stage biotechnology firm Recursion announced the release of an open-source biological dataset, RxRx1, which the company has been building for more than five years. The dataset is composed of ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors Salt Lake ...
Recursion Pharmaceuticals' market cap currently stands at just over $2 billion. The math is simple: To double, the company will need its market cap to increase to more than $4 billion. The best way to ...
Recursion Pharmaceuticals leverages an artificial intelligence platform to decode biology and automate the drug discovery process. Summit Therapeutics is focused on its lead oncology candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results